Memorial Sloan Kettering Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Phase 1
Completed
- Conditions
- Ovarian CancerTesticular Germ Cell TumorExtragonadal Germ Cell Tumor
- Interventions
- Biological: filgrastimProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 108
- Registration Number
- NCT00002558
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
Phase 2
Completed
- Conditions
- Neuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004110
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00049101
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002982
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
Phase 1
Completed
- Conditions
- Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003342
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Phase 2
Completed
- Conditions
- Bladder CancerUrethral Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00002684
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Phase 1
Completed
- Conditions
- Brain and Central Nervous System TumorsIntraocular MelanomaLung CancerMelanoma (Skin)NeuroblastomaRetinoblastomaSarcoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003022
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
Phase 1
Completed
- Conditions
- Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003105
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
Phase 2
Completed
- Conditions
- Neuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00002560
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00036972
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath